← Back to Search

Dual-Energy CT Scan for Carcinoid Tumors

Phase < 1
Waitlist Available
Led By Ajaykumar Morani
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with endoscopic biopsy proven carcinoid
Patients with increased serum and urinary markers suggestive of carcinoid
Must not have
Patients who have already had their primary GI carcinoid resected
Contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at using a special CT scan to detect gastrointestinal carcinoid tumors. The scan uses x-rays and a computer to create images of inside the body.

Who is the study for?
This trial is for individuals with signs of carcinoid syndrome, increased markers indicating carcinoid, confirmed diagnosis through biopsy, or metastases known to be from a carcinoid tumor. They must be scheduled for a CT scan and have consented to participate. Pregnant individuals or those allergic to contrast agents used in scans cannot join.
What is being tested?
The study is examining the effectiveness of Dual Energy Computed Tomography (DECT) in detecting gastrointestinal carcinoid tumors during routine CT scans. Researchers aim to determine if DECT can enhance the imaging and identification of these tumors.
What are the potential side effects?
While there are no direct side effects from the dual energy CT itself being tested, participants may experience reactions related to the use of intravenous contrast agents such as allergic reactions or kidney issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My biopsy confirmed I have carcinoid cancer.
Select...
My tests show markers indicating I might have carcinoid cancer.
Select...
My cancer spread is confirmed as carcinoid through a biopsy.
Select...
I show symptoms of carcinoid syndrome.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My primary GI carcinoid tumor has been surgically removed.
Select...
I cannot have IV contrast due to an allergy, kidney issues, or pregnancy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (dual energy CT scan)Experimental Treatment1 Intervention
Patients undergo one dual energy CT scan during scheduled CT scan.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dual-Energy Computed Tomography
2018
N/A
~50

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,737 Total Patients Enrolled
5 Trials studying Carcinoid Tumor
210 Patients Enrolled for Carcinoid Tumor
Ajaykumar MoraniPrincipal InvestigatorM.D. Anderson Cancer Center
Vikas KundraPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
350 Total Patients Enrolled

Media Library

Dual-Energy Computed Tomography Clinical Trial Eligibility Overview. Trial Name: NCT04993261 — Phase < 1
Carcinoid Tumor Research Study Groups: Diagnostic (dual energy CT scan)
Carcinoid Tumor Clinical Trial 2023: Dual-Energy Computed Tomography Highlights & Side Effects. Trial Name: NCT04993261 — Phase < 1
Dual-Energy Computed Tomography 2023 Treatment Timeline for Medical Study. Trial Name: NCT04993261 — Phase < 1
~13 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top